Abstract # Abstract Text:
|
|
- Roger Holmes
- 5 years ago
- Views:
Transcription
1 Page 1 of 6 Abstract # MAP plus maintenance pegylated interferon α-2b (MAP-IFN) versus MAP alone in patients (pts) with resectable high-grade osteosarcoma and good histological response to preoperative MAP: First results of the EURAMOS- 1 good response randomization. Stefan S. Bielack, Sigbjorn Smeland, Jeremy Whelan, Neyssa Marina, Jane Hook, Gordana Jovic, Mark D. Krailo, Trude Butterfass-Bahloul, Thomas Kühne, Mikael Eriksson, Lisa A. Teot, Hans Gelderblom, Leo Kager, Kirsten Sundby Hall, Richard Greg Gorlick, R. Lor Randall, Pancras C. W. Hogendoorn, Gabriele Calaminus, Matthew Robert Sydes, Mark L. Bernstein; Klinikum Stuttgart, Olgahospital, Cooperative Osteosarcoma Study Group (COSS), Stuttgart, Germany; Oslo University Hospital, The Norwegian Radium Hospital, Scandinavian Sarcoma Group, Oslo, Norway; University College London Hospitals NHS Foundation Trust, United Kingdom; Stanford University, School of Medicine, Palo Alto, CA; MRC Clinical Trials Unit, ; Children's Oncology Group, Arcadia, CA; Center for Clinical Trials, University of Muenster, Muenster, Germany; University Children s Hospital Basel, Basel, Switzerland; Skane University Hospital and Lund University, Lund, Sweden; Children's Hospital Boston, Boston, MA; Department of Clinical Oncology, Leiden University Medical Center, Leiden, Netherlands; St Anna's Children's Hospital, Vienna, Austria; The Children's Hospital, Bronx, NY; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; Department of Pathology, Leiden University Medical Center, Leiden, Netherlands; University Hospital of Muenster, Muenster, Germany; IWK Health Center, Dalhousie University, Halifax, NS Abstract Text: Background: EURAMOS 1 (NCT ) is an international Phase III randomized controlled trial (RCT) investigating treatment optimization in osteosarcoma on the basis of histological response to preoperative chemotherapy (CT). It is the largest RCT conducted in this rare cancer. In pts with good response to induction CT (GR; <10% viable tumor at resection), efficacy of maintenance therapy with pegylated interferon α 2b (IFN) was investigated. Methods: Pts 40yrs with resectable localized or primary metastatic high-grade extremity or axial osteosarcoma were eligible for registration at diagnosis. Eligibility for randomization included: i) receipt of 2 cycles preop methotrexate, doxorubicin, cisplatin (MAP); ii) complete macroscopic resection of primary tumor; iii) no disease progression. GR pts were randomized (1:1) after surgery to 4 cycles MAP ± IFN. IFN was given μg/kg/wk post CT to 2yr post registration. Primary endpoint: event free survival (EFS); secondary: overall survival (OS), toxicity, quality of life. The trial design sought improved 3yr EFS from 70% to 80% (80% power, 2-sided alpha 5%). Final analysis planned after 147 EFS events pts were registered (Apr 2005 to Jun 2011) from 17 countries, 326 sites. Of 2080 with recorded histological response to preop CT, 1034 had a GR of whom 715 consented to randomization (358 MAP, 357 MAP-IFN). Median follow-up is 3.1 yrs. The final analysis of EFS is planned for Feb 2013 when the planned number of events will have been reported. Final results will be presented for EFS: an estimate of relative treatment effect (using a Cox Model if hazards are proportional or Restricted Mean Survival Time if not) and the two arms compared using a logrank test. In addition, an estimate of the accumulating treatment effect on OS will be presented for context (IDMC agreed). Toxicity data will also be presented.
2 Page 2 of 6 Title:MAP plus maintenance pegylated interferon α-2b (MAP-IFN) versus MAP alone in patients (pts) with resectable high-grade osteosarcoma and good histological response to preoperative MAP: First results of the EURAMOS-1 good response randomization. Submitter's Address:S.Bielack@klinikum-stuttgart.de Is this a late-breaking abstract?yes If your late-breaking abstract is deemed acceptable for publication only, would you like to have it automatically withdrawn?yes Is this abstract a clinical trial?yes Is this clinical trial registered?yes Registry Name:Clinicaltrials.gov Registration Number:NCT Research Funding Source:Other Research Funding Source Name:NIH, European funding via European Science Foundation EUROCORES (EU FP6) Did the trial accrue its first patient before or after April 29, 2004?After Would like to be considered for a Merit Award:No Trial Type:Phase III Research Category:Clinical Continued Trial Accrual:No Recieved Grant funding:no Relevant to geriatric oncology:no Sponsor: Mark L. Bernstein, MD First Author Presenting Author Stefan S. Bielack, MD PhD Klinikum Stuttgart, Olgahospital, Cooperative Osteosarcoma Study Group (COSS) Stuttgart, Germany Phone Number: S.Bielack@klinikum-stuttgart.de Second Author Sigbjorn Smeland, MD PhD Oslo University Hospital, The Norwegian Radium Hospital, Scandinavian Sarcoma Group Oslo, Norway Phone Number: sibjorn.smeland@radiumhospital.no Third Author Jeremy Whelan, MD University College London Hospitals NHS Foundation Trust
3 Page 3 of 6 Phone Number: jeremy.whelan@uclh.nhs.uk Fourth Author Neyssa Marina, MD MS Stanford University, School of Medicine Palo Alto, CA Phone Number: Fax Number: neyssa.marina@stanford.edu Fifth Author Jane Hook, MBBChir MRC Clinical Trials Unit Phone Number: jmhook@doctors.org.uk Sixth Author Gordana Jovic, PhD MRC Clinical Trials Unit Phone Number: goj@ctu.mrc.ac.uk Seventh Author Mark D. Krailo, PhD Children's Oncology Group Arcadia, CA Phone Number: Fax Number: mkrailo@childrensoncologygroup.org Eighth Author Trude Butterfass-Bahloul, MD Center for Clinical Trials, University of Muenster Muenster,
4 Page 4 of 6 Germany Phone Number: +49 (0) butterft@ukmuenster.de Ninth Author Thomas Kühne, MD University Children s Hospital Basel Spitalstrasse 33 Basel, Switzerland Phone Number: thomas.kuehne@ukbb.ch Tenth Author Mikael Eriksson, MD PhD Skane University Hospital and Lund University Lund, Sweden Phone Number: MIKAEL.ERIKSSON@MED.LU.SE Eleventh Author Lisa A. Teot, MD Children's Hospital Boston Boston, MA Phone Number: lisa.teot@childrens.harvard.edu Twelfth Author Hans Gelderblom, MD PhD Department of Clinical Oncology, Leiden University Medical Center Albinusdreef 2 Leiden, Netherlands Phone Number: Fax Number: a.j.gelderblom@lumc.nl Thirteenth Author Leo Kager, MD St Anna's Children's Hospital
5 Page 5 of 6 Kinderspitalgasse 6 Vienna, Austria Phone Number: leo.kager@stanna.at Fourteenth Author Kirsten Sundby Hall, MD PhD Oslo University Hospital, The Norwegian Radium Hospital, Scandinavian Sarcoma Group Oslo, Norway Phone Number: / Kirsten.Sundby.Hall@oslo-universitetssykehus.no Fifteenth Author Richard Greg Gorlick, MD The Children's Hospital Bronx, NY Phone Number: Fax Number: rgorlick@montefiore.org Sixteenth Author R. Lor Randall, MD Huntsman Cancer Institute, University of Utah 2000 Circle of Hope Salt Lake City, UT Phone Number: r.lor.randall@hci.utah.edu Seventeenth Author Pancras C. W. Hogendoorn, MD PhD Department of Pathology, Leiden University Medical Center Leiden, Netherlands Phone Number: p.c.w.hogendoorn@lumc.nl Eighteenth Author Gabriele Calaminus, MD
6 Page 6 of 6 University Hospital of Muenster Albert-Schweitzer-Strasse 33 Muenster, Germany Phone Number: gabriele.calaminus@ukmuenster.de Nineteenth Author Matthew Robert Sydes, CStat MRC Clinical Trials Unit Aviation House 125 Kingsway Phone Number: 44 (0) Fax Number: 44 (0) matthew.sydes@ctu.mrc.ac.uk Twentieth Author Mark L. Bernstein, MD IWK Health Center, Dalhousie University Halifax, NS B3K 6R8 Canada Phone Number: mark.bernstein@iwk.nshealth.ca
First results of the EURAMOS-1 Good Response randomization
plus maintenance pegylated interferon -2b (ifn) versus alone in patients with resectable high-grade osteosarcoma and good histological response to preoperative : First results of the EURAMOS-1 Good Response
More information) ( , 2005, 30, 2011, ); ) 61 1 ; IWK (IQR
Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled
More informationSolid organ transplant after treatment for childhood cancer: A report from the Childhood Cancer Survivor Study.
Your abstract submission has been received You have submitted the following abstract to the 2017 ASCO Annual Meeting (June 2-6, 2017). Receipt of this notice does not guarantee that your submission was
More informationREDUCTION (MBSR) ON LYMPHOCYTE RECOVERY AFTER BREAST CANCER TREATMENT
Page 1 of 6 Abstract #3093 EFFECTS of Mindfulness BASED Stress REDUCTION (MBSR) ON LYMPHOCYTE RECOVERY AFTER BREAST CANCER TREATMENT Cecile A. Lengacher, RN, 1, Thomas Klein, 2, Raymond Widen, 1, Shirley
More informationImproving Randomisation rates: Practical Steps
Improving Randomisation rates: Practical Steps Dorothe Carrle Cooperative Osteosarcoma Study Group - COSS Stuttgart This course, as part of the European Science Foundation EUROCORES Programme ECT, is supported
More informationAccess to Clinical Trials International Initiatives
Access to Clinical Trials International Initiatives Stefan Bielack Cooperative Osteosarcoma Study Group COSS Stuttgart Cancer Center Klinikum Stuttgart Olgahospital Zentrum für Kinder-, Jugend- und Frauenmedizin
More informationFollow-up practices for high-grade extremity Osteosarcoma
Rothermundt et al. BMC Cancer (2016) 16:301 DOI 10.1186/s12885-016-2333-y RESEARCH ARTICLE Open Access Follow-up practices for high-grade extremity Osteosarcoma Christian Rothermundt 1*, Beatrice M. Seddon
More informationPerioperative chemotherapy in the treatment of osteosarcoma: a 26 year single institution review
DOI 10.1186/s13569-015-0032-0 CLINICAL SARCOMA RESEARCH RESEARCH Open Access Perioperative chemotherapy in the treatment of osteosarcoma: a 26 year single institution review G M O Kane 1*, K A Cadoo 2,
More informationScandinavian Sarcoma Group. Ass. Prof. Otte Brosjö,, Karolinska Hospital, Stockholm
Scandinavian Sarcoma Group Ass. Prof. Otte Brosjö,, Karolinska Hospital, Stockholm The Scandinavian Sarcoma Group Organisation of Care and Research Quality management - the SSG experience Multidisciplinary
More information11 th Working Groups Meeting of the Scandinavian Sarcoma Group
11 th Working Groups Meeting of the Scandinavian Sarcoma Group Scandinavian Sarcoma Group 1979 Version 2005-10-17 www.ssg-org.net ssg@med.lu.se November, 28-29, 2005 Copenhagen INTRODUCTION Welcome to
More informationBONE SARCOMA. esmo.org
BONE SARCOMA Stefan Bielack Cooperative Osteosarcoma Study Group COSS Klinikum Stuttgart Olgahospital Pädiatrie 5 (Onkologie, Hämatologie, Immunologie) s.bielack@klinikum-stuttgart.de esmo.org If you
More informationChemotherapy in osteosarcoma: The Scandinavian Sarcoma Group experience
Chemotherapy in osteosarcoma: The Scandinavian Sarcoma Group experience Smeland, S.; Wiebe, Thomas; Böhling, T.; Brosjö, O.; Jonsson, Kjell; Alvegård, Thor Published in: Acta Orthopaedica Scandinavica
More informationAssessing quality of life in sarkoma trials
Pan-European Clinical Trials under current EU regulations: A training course for data managers, study nurses, and junior clinical investigators London, January 24/25, 2008 Assessing quality of life in
More informationShort Study Report for Health Authorities
the Active Title of the Study Randomised trial of single agent doxorubicin versus doxorubicin plus ifosfamide in the first line treatment of advanced or metastatic soft tissue sarcoma Investigators & Study
More informationNew Treatment Strategies in Osteosarcoma. PD Dr. Claudia Blattmann, Prof. Dr. Stefan Bielack Olgahospital Klinikum Stuttgart Germany
New Treatment Strategies in Osteosarcoma PD Dr. Claudia Blattmann, Prof. Dr. Stefan Bielack Olgahospital Klinikum Stuttgart Germany Introduction Most common bone tumor in children, adolescents and young
More informationALL-RELAPSE GROUP Päivi Lähteenmäki on behalf of the group
ALL-RELAPSE GROUP 18.11.2014 Päivi Lähteenmäki on behalf of the group Meeting in Bergen and 2 telephone meetings (Sept, Oct) IntReALL-group in Lissabon (September, Thomas F) IntReALL SR : Denmark has registered
More informationManagement of high-grade bone sarcomas over two decades: The Norwegian Radium Hospital experience
Acta Oncologica, 2006; 45: 38 /46 ORIGINAL ARTICLE Management of high-grade bone sarcomas over two decades: The Norwegian Radium Hospital experience LIV HEGE AKSNES 1, KIRSTEN SUNDBY HALL 1, GUNNAR FOLLERAAS
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 17 November 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 17 November 2010 MEPACT 4 mg, powder for suspension for infusion B/1 (CIP code: 398331 6) Applicant : IDM PHARMA S.A.S
More informationOsteosarcoma (Brief information)
Osteosarcoma (Brief information) Copyright 2017 Competence Network Paediatric Oncology and haematology Author: Maria Yiallouros, Dr. med. habil. Gesche Tallen, created 2009/02/12, Editor: Maria Yiallouros,
More information14 th Working Groups Meeting of the Scandinavian Sarcoma Group Copenhagen
14 th Working Groups Meeting of the Scandinavian Sarcoma Group Copenhagen Final Program Date: November 30 December 2, 2008 Place: DGI-byens Hotel, DGI-byen, Tietgensgade 65, DK-1704 Copenhagen V Tel: +45
More informationResearch Article Prognostic Factors and Treatment Results of High-Grade Osteosarcoma in Norway: A Scope Beyond the Classical Patient
Sarcoma Volume 25, Article ID 56843, 4 pages http://dx.doi.org/.55/25/56843 Research Article Prognostic Factors and Treatment Results of High-Grade Osteosarcoma in Norway: A Scope Beyond the Classical
More informationUsing Technology to Assess and Manage Symptoms in Cancer Care
Using Technology to Assess and Manage Symptoms in Cancer Care Roma Maguire Professor of ehealth School of Health Sciences University of Surrey Tuesday, 29 November 2016 1 Cancer tidal wave on the horizon
More informationJ Clin Oncol 30: by American Society of Clinical Oncology INTRODUCTION
VOLUME 30 NUMBER 17 JUNE 10 2012 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Neoadjuvant Chemotherapy With Methotrexate, Cisplatin, and Doxorubicin With or Without Ifosfamide in Nonmetastatic
More informationFlexible trial design in practice dropping and adding arms in STAMPEDE: a multi-arm multi-stage randomised controlled trial (MRC PR08, CRUK/06/019)
Flexible trial design in practice dropping and adding arms in STAMPEDE: a multi-arm multi-stage randomised controlled trial (MRC PR08, CRUK/06/019) Matthew Sydes MRC Clinical Trials Unit, London, UK ND
More informationLONDON CANCER NEW DRUGS GROUP RAPID REVIEW
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Adjuvant imatinib after complete resection of primary gastrointestinal stromal tumour (GIST) in patients at high risk of relapse May 2012 Summary NICE guidance
More informationProspective Trial for the Diagnosis and Treatment of Intracranial Germ Cell Tumors (SIOPCNSGCTII)
1 von 9 10.12.2013 09:03 A service of the U.S. National Institutes of Health Trial record 1 of 1 for: UKM08_0057 Previous Study Return to List Next Study Prospective Trial for the Diagnosis and Treatment
More informationWest Campus Curricular Schedule
. ṢṬỤ. ḌẸṆ. Ṭ. ẠḌ. ṂỊṆỊṢṬṚ. ẠṬ. IṾẸ. Ṣ. ẸṚ. ṾỊC.ẸṢ... West Campus Curricular Schedule This schedule gives a general idea of a class day by Quarter at the West Campus. *Actual class times change each term
More informationPrimary Endpoint The primary endpoint is overall survival, measured as the time in weeks from randomization to date of death due to any cause.
CASE STUDY Randomized, Double-Blind, Phase III Trial of NES-822 plus AMO-1002 vs. AMO-1002 alone as first-line therapy in patients with advanced pancreatic cancer This is a multicenter, randomized Phase
More informationHow to improve the reliability of Single Arm Trials
Workshop on Single Arm Trials in Oncology Products EMA, London, June 30, 2016 How to improve the reliability of Single Arm Trials Paolo Bruzzi Clinical Epidemiology Unit IRCCS San Martino-IST - National
More information20 th Working Committee Meeting of the Scandinavian Sarcoma Group Malmö
20 th Working Committee Meeting of the Scandinavian Sarcoma Group Malmö Preliminary program Version 2015-11-02 Date: November 30 December 1, 2015 Place: World Trade Center Malmö Jungmansgatan 12 SE-211
More informationEpendymoma Programme Synopsis
Ependymoma Programme Synopsis TITLE SPONSOR PROTOCOL NUMBER EUDRACT NUMBER NATIONAL INVESTIGATOR- COORDINATOR SIOP Ependymoma program II: An International Clinical Program for the diagnosis and treatment
More informationNon-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist
Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist Vichien Srimuninnimit, MD. Medical Oncology Division Faculty of Medicine, Siriraj Hospital Outline Resectable NSCLC stage
More informationWe have studied 560 patients with osteosarcoma of a
Osteosarcoma of the limb AMPUTATION OR LIMB SALVAGE IN PATIENTS TREATED BY NEOADJUVANT CHEMOTHERAPY G. Bacci, S. Ferrari, S. Lari, M. Mercuri, D. Donati, A. Longhi, C. Forni, F. Bertoni, M. Versari, E.
More informationClinical Research in Rare Cancers. Friday 10 th February Matt Seymour & Nicola Keat
Clinical Research in Rare Cancers Friday 10 th February 2012 Matt Seymour & Nicola Keat Rare cancer is a common disease Rare Cancer : [prevalence
More informationPRELIMINARY PROGRAM (Version ) The 36 th Meeting of the Scandinavian Sarcoma Group
PRELIMINARY PROGRAM (Version 2012-09-28) The 36 th Meeting of the Scandinavian Sarcoma Group Helsinki Date: October 9-11, 2013 Place: Hotel Crowne Plaza Mannerheimentie 50 Helsinki 00260 Finland Hotel
More informationOverview of Epidemiological Studies and Trends in Paediatric CT use. Mark S. Pearce, PhD
Overview of Epidemiological Studies and Trends in Paediatric CT use Mark S. Pearce, PhD CT scan usage A very useful tool Introduced in 1973 for head scanning Available worldwide at over 30,000 centres
More informationResearch Article Age, Tumor Characteristics, and Treatment Regimen as Event Predictors in Ewing: A Children s Oncology Group Report
Sarcoma Volume 2015, Article ID 927123, 8 pages http://dx.doi.org/10.1155/2015/927123 Research Article Age, Tumor Characteristics, and Treatment Regimen as Event Predictors in Ewing: A Children s Oncology
More informationFINAL PROGRAM. The 36 th Meeting of the Scandinavian Sarcoma Group
FINAL PROGRAM The 36 th Meeting of the Scandinavian Sarcoma Group Helsinki Date: October 9-11, 2013 Place: Hotel Crowne Plaza Mannerheimentie 50 Helsinki 00260 Finland Hotel Front Desk +358-9-2521 0000
More informationIN THE UNITED STATES PATENT AND TRADEMARK OFFICE. For PROVISIONAL APPLICATION FOR LETTERS PATENT. Inventor: David Rexford. Logical Phonetic Alphabet
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE PROVISIONAL APPLICATION FOR LETTERS PATENT For Logical Phonetic Alphabet Inventor: David Rexford Logical Phonetic Alphabet Inventor: David Rexford FIELD
More informationINTERGROUP STUDY (SFCE / GSF-GETO) ZOLEDRONATE OSTEOSARCOMA
LB1 Mise en place du : OS 2006 study SARCOME 09/0603 (N EudraCT 2006-00337727) INTERGROUP STUDY (SFCE / GSF-GETO) ZOLEDRONATE OSTEOSARCOMA PROTOCOL FOR TREATMENT of OSTEOSARCOMA in CHILDREN, ADOLESCENTS
More informationThe case against maintenance rituximab in Follicular lymphoma. Jonathan W. Friedberg M.D., M.M.Sc.
The case against maintenance rituximab in Follicular lymphoma Jonathan W. Friedberg M.D., M.M.Sc. Follicular lymphoma: What are goals of treatment? Change natural history of disease: Decrease transformation
More informationFlorida Campus Sample Curricular Schedule
ḌẸṆ Ṭ ẸṢ This schedule gives a general idea of a class day by quarter at the Florida Campus *Actual class times change each term depending on the number of students enrolled and the required number of
More informationMedicinae Doctoris. One university. Many futures.
Medicinae Doctoris The Before and The After: Can chemotherapy revise the trajectory of gastric and esophageal cancers? Dr. David Dawe MD, FRCPC Medical Oncologist Assistant Professor Disclosures None All
More informationAdjuvant Therapy of High Risk Melanoma
Adjuvant Therapy of High Risk Melanoma William Sharfman, MD, FACP Associate Professor of Oncology and Dermatology Johns Hopkins University School of Medicine July 5, 2012 Adjuvant options for Stage IIB/C
More informationTumor Necrosis in Pediatric Osteosarcoma: Impact of Modern Therapies
DOCTYPE = ARTICLE Tumor Necrosis in Pediatric Osteosarcoma: Impact of Modern Therapies Eleanor Hendershot, MN, RN, ACNP Alberto Pappo, MD David Malkin, MD Lillian Sung, MD Tumor necrosis following preoperative
More informationThe 39 th Plenary meeting & 40 year s Jubilee meeting of the Scandinavian Sarcoma Group
The 39 th Plenary meeting & 40 year s Jubilee meeting of the Scandinavian Sarcoma Group The 11 th meeting of the Scandinavian Sarcoma Group for Nurses & Physiotherapists May 8-10, 2019 Bergen PRELIMINARY
More informationNational Horizon Scanning Centre. Imatinib (Glivec) for adjuvant therapy in gastrointestinal stromal tumours. August 2008
Imatinib (Glivec) for adjuvant therapy in gastrointestinal stromal tumours August 2008 This technology summary is based on information available at the time of research and a limited literature search.
More informationFINAL PROGRAM. The 36 th Meeting of the Scandinavian Sarcoma Group
FINAL PROGRAM The 36 th Meeting of the Scandinavian Sarcoma Group Helsinki Date: October 9-11, 2013 Place: Hotel Crowne Plaza Mannerheimentie 50 Helsinki 00260 Finland Hotel Front Desk +358-9-2521 0000
More information22 nd Working Group Meeting of the Scandinavian Sarcoma Group
22 nd Working Group Meeting of the Scandinavian Sarcoma Group January 22-23, 2018 Malmö PROGRAM Version 2017-11-02 www.ssg-org.net Introduction Welcome to the 22 nd Scandinavian Sarcoma Group Working Committee
More information23 rd Working Group Meeting of the Scandinavian Sarcoma Group
23 rd Working Group Meeting of the Scandinavian Sarcoma Group December 3-4, 2018 Malmö PROGRAM www.ssg-org.net Introduction Welcome to the 23 rd Scandinavian Sarcoma Group Working Committee Meeting in
More information21 st Working Group Meeting of the Scandinavian Sarcoma Group
21 st Working Group Meeting of the Scandinavian Sarcoma Group December 5-6, 2016 Malmö PROGRAM Version 2016-11-02 www.ssg-org.net Introduction Welcome to the 21 st Scandinavian Sarcoma Group Working Committee
More informationStandard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant
Standard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant Pr Philippe Moreau University Hospital, Nantes, France MP: Standard of care until 2007 J Clin Oncol
More informationoriginal articles Osteosarcoma of the mobile spine
Annals of Oncology Annals of Oncology 24: 2190 2195, 2013 doi:10.1093/annonc/mdt154 Published online 23 April 2013 Osteosarcoma of the mobile spine K. Zils 1 *, S. Bielack 1,2, M. Wilhelm 1, M. Werner
More informationImmunotherapy in the Adjuvant Setting for Melanoma: What You Need to Know
Immunotherapy in the Adjuvant Setting for Melanoma: What You Need to Know Jeffrey Weber, MD, PhD Laura and Isaac Perlmutter Cancer Center NYU Langone Medical Center New York, New York What Is the Current
More informationTitle: Non-small cell lung carcinoma in an adolescent, manifested by acute paraplegia due to spinal metastases - case report
Author's response to reviews Title: Non-small cell lung carcinoma in an adolescent, manifested by acute paraplegia due to spinal metastases - case report Authors: Ulrike Ackert (ulrike_ackert@hotmail.com)
More informationWho is the Ideal Candidate for PEG Intron?
Who is the Ideal Candidate for PEG Intron? Sanjiv S. Agarwala, MD Chief, Oncology & Hematology St. Luke s Cancer Center Professor, Temple University School of Medicine Philadelphia, PA, USA Overview Introduction
More informationMEETING SUMMARY ESMO 2018, Munich, Germany. Dr. Jenny Seligmann University of Leeds, UK HIGHLIGHTS ON COLORECTAL CANCER
MEETING SUMMARY ESMO 2018, Munich, Germany Dr. Jenny Seligmann University of Leeds, UK HIGHLIGHTS ON COLORECTAL CANCER DISCLAIMER Please note: The views expressed within this presentation are the personal
More informationImmune Therapy in Clear Cell Ovarian Cancer (ITICC) Hal Hirte Canadian Cancer Clinical Trials Group
Immune Therapy in Clear Cell Ovarian Cancer (ITICC) Hal Hirte Canadian Cancer Clinical Trials Group Results of Phase II Study of Durvalumab and Tremelimumab in recurrent clear cell ovarian cancer Trial
More informationintent treatment be in the elderly?
Gastric cancer: How strong can curative intent treatment be in the elderly? Caio Max S. Rocha Lima, M.D. Professor of Medicine University of Miami & Sylvester Cancer Center Gastric cancer: epidemiology
More informationOverall survival: 1 st line therapy
1 3 Overall survival: 1 st line therapy 2-year OS phase III studies mm Prices per month of oncology medicin Bloomberg Business weekly 26 Feb 2015 Presented By Veena Shankaran at 2016 ASCO Annual Meeting
More information3/8/2014. Case Presentation. Primary Treatment of Anal Cancer. Anatomy. Overview. March 6, 2014
Case Presentation Primary Treatment of Anal Cancer 65 year old female presents with perianal pain, lower GI bleeding, and anemia with Hb of 7. On exam 6 cm mass protruding through the anus with bulky R
More informationWCPT COUNTRY PROFILE December 2017 SWEDEN
WCPT COUNTRY PROFILE December 2017 SWEDEN SWEDEN NUMBERS WCPT Members Practising physical therapists 11,043 Total number of physical therapist members in your member organisation 17,906 Total number of
More informationNeo- and adjuvant treatment for gastric cancer: The role of chemotherapy
Anna Dorothea Wagner, PD & MER Department of Oncology University of Lausanne Neo- and adjuvant treatment for gastric cancer: The role of chemotherapy Structure 1. Background and overview 2. Adjuvant chemotherapy:
More information8 November Zurich
DENTAL IMPLANTS VS. BISPHOSPHONATES from science to clinical application 8 November 2013 - Zurich Welcome to Zurich! It is with great pleasure that we invite you to the first international symposium dealing
More informationWhere are we with radiotherapy for biliary tract cancers?
Where are we with radiotherapy for biliary tract cancers? Professor Maria A. Hawkins Associate Professor in Clinical Oncology MRC Group Leader/Honorary Consultant Clinical Oncologist CRUK MRC Oxford Institute
More informationAdvances in gastric cancer: How to approach localised disease?
Advances in gastric cancer: How to approach localised disease? Andrés Cervantes Professor of Medicine Classical approach to localised gastric cancer Surgical resection Pathology assessment and estimation
More informationCost-effectiveness assessment of interferon alfa-2b as adjuvant therapy of high-risk resected cutaneous melanoma Hillner B E
Cost-effectiveness assessment of interferon alfa-2b as adjuvant therapy of high-risk resected cutaneous melanoma Hillner B E Record Status This is a critical abstract of an economic evaluation that meets
More informationThe 35 th Meeting of the Scandinavian Sarcoma Group. Abstracts. Malmö May 4 6, L1 Imatinib in non-gist solid tumors
The 35 th Meeting of the Scandinavian Sarcoma Group Malmö May 4 6, 2011 L1 Imatinib in non-gist solid tumors P. Casali National Cancer Institute, Milan, Italy L2 EURAMOS-1, A randomized European/American
More informationClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt Release Date: June 25, ClinicalTrials.gov ID: NCT
ClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt Release Date: June 25, 2014 ClinicalTrials.gov ID: NCT00372385 Study Identification Unique Protocol ID: VX05-950-104EU Brief Title:
More informationUPDATE FROM ASCO GU FEBRUARY 2018, SAN FRANCISCO, USA. Prof. David Pfister University Hospital of Cologne Germany RENAL CELL CARCINOMA
UPDATE FROM ASCO GU FEBRUARY 2018, SAN FRANCISCO, USA Prof. David Pfister University Hospital of Cologne Germany RENAL CELL CARCINOMA DISCLAIMER Please note: The views expressed within this presentation
More informationDENMARK. WCPT COUNTRY PROFILE December 2018
DENMARK WCPT COUNTRY PROFILE December 2018 DENMARK NUMBERS 14000 12000 10000 8000 6000 4000 2000 0 Physical therapists in the country Members in MO 11,720 12,975 Total PTs in country 800000 700000 600000
More informationASCONA 07/11/08 PAEDIATRIC ONCOLOGY. 2 nd ESO-SIOPE MASTERCLASS IN November 2008 Ascona, Switzerland
MASTERCLASS ASCONA 07/11/08 2 nd ESO-SIOPE MASTERCLASS IN PAEDIATRIC ONCOLOGY 7-13 November 2008 Ascona, Switzerland Chair: R. Riccardi, IT - M.C.G. Stevens, UK - A. Eggert, DE Educational Advisor: W.
More informationYour abstract submission has been received. Click here to print this page now.
Your abstract submission has been received Click here to print this page now. You have submitted the following abstract to 2017 AABB Annual Meeting. Receipt of this notice does not guarantee that your
More informationA Summary of Childhood Cancer Statistics in Australia,
What is the Australian Paediatric Cancer Registry (APCR)? The APCR is one of only a few national registries of childhood cancer in the world. It covers all Australian children aged 0-14 years old at diagnosis.
More informationClinical Study Metastasectomy of Pulmonary Metastases from Osteosarcoma: Prognostic Factors and Indication for Repeat Metastasectomy
Respiratory Medicine Volume 2015, Article ID 570314, 5 pages http://dx.doi.org/10.1155/2015/570314 Clinical Study Metastasectomy of Pulmonary Metastases from Osteosarcoma: Prognostic Factors and Indication
More informationEuropean Experience and Perspective on Assessing Value for Oncology Products. Michael Drummond Centre for Health Economics, University of York
European Experience and Perspective on Assessing Value for Oncology Products Michael Drummond Centre for Health Economics, University of York Outline of Presentation The European landscape on access to
More informationLONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Erlotinib for the third or fourth-line treatment of NSCLC January 2012
Disease background LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Erlotinib for the third or fourth-line treatment of NSCLC January 2012 Lung cancer is the second most common cancer in the UK (after breast),
More informationPERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER. Virginie Westeel Chest Disease Department University Hospital Besançon, France
PERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER Virginie Westeel Chest Disease Department University Hospital Besançon, France LEARNING OBJECTIVES 1. To understand the potential of perioperative
More information19 th Working Committee Meeting of the Scandinavian Sarcoma Group Malmö
19 th Working Committee Meeting of the Scandinavian Sarcoma Group Malmö Final program Date: February 2-4, 2014 World Trade Center Malmö Jungmansgatan 12 SE-211 19 Malmö Phone: +46 40 627 11 00 E-mail:
More informationPH.D. PROGRAM IN CLINICAL PSYCHOLOGY THE CITY UNIVERSITY OF NEW YORK. Prof. Elliot L. Jurist Fall 2015
PH.D. PROGRAM IN CLINICAL PSYCHOLOGY THE CITY UNIVERSITY OF NEW YORK Prof. Elliot L. Jurist Fall 2015 Office: NAC 8/109 Office Hours: Tel. (212) 650-5676 Tu 9:00 am and by appt. Email: ejurist5@gmail.com
More informationWCPT COUNTRY PROFILE December 2017 SERBIA
WCPT COUNTRY PROFILE December 2017 SERBIA SERBIA NUMBERS WCPT Members Practising physical therapists 622 Total number of physical therapist members in your member organisation 3,323 Total number of practising
More informationTHE ROLE OF RADIATION THERAPY IN MANAGEMENT OF PANCREATIC ADENOCARCINOMA. TIMUR MITIN, MD, PhD
THE ROLE OF RADIATION THERAPY IN MANAGEMENT OF PANCREATIC ADENOCARCINOMA TIMUR MITIN, MD, PhD RESECTABLE DISEASE MANAGEMENT: RESECTABLE DISEASE Resection offers the only possibility of long term survival
More informationMental Health Medi-Cal: 11 Required Assessment Elements
Mental Health Medi-Cal: 11 Required Assessment Elements 1. Presenting Problem 2. Relevant Conditions and Psychosocial Factors 3. Mental Health History 4. Medical History 5. Medications 6. Substance Exposure/Substance
More informationAmreen Husain, 10 Eric P. Winer, 11 Sylvia Adams, 12 Peter Schmid 13
IMpassion130: Efficacy in immune biomarker subgroups from the global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab + nab-paclitaxel in patients with treatment-naive, locally
More informationMini J.Elnaggar M.D. Radiation Oncology Ochsner Medical Center 9/23/2016. Background
Mini J.Elnaggar M.D. Radiation Oncology Ochsner Medical Center 9/23/2016 Background Mostly adenocarcinoma (scc possible, but treated like anal cancer) 39, 220 cases annually Primary treatment: surgery
More informationin combination with cisplatin as first-line doublet 3 as maintenance agent following non-pemetrexed platinum doublet 4
Overall survival (OS) results from PARAMOUNT study of maintenance plus best supportive care (BSC) versus plus BSC, immediately after induction with - Cisplatin, in patients with advanced Nonsquamous Non-small
More informationWhen to Integrate Surgery for Metatstatic Urothelial Cancers
When to Integrate Surgery for Metatstatic Urothelial Cancers Wade J. Sexton, M.D. Senior Member and Professor Department of Genitourinary Oncology Moffitt Cancer Center Case Presentation #1 67 yo male
More informationESSO Advanced Course on Primary Liver Tumours
ESSO Advanced Course on Primary Liver Tumours 24-25 April 2014 LIVERPOOL (UK) Endorsed by ESSO Advanced Course on Primary Liver Tumours Chair Hassan Malik, University Hospital Aintree NHS Trust, Liverpool,
More informationErlotinib (Tarceva) for non small cell lung cancer advanced or metastatic maintenance monotherapy
Erlotinib (Tarceva) for non small cell lung cancer advanced or metastatic maintenance monotherapy September 2008 This technology summary is based on information available at the time of research and a
More informationEffectiveness of multi-drug regimen chemotherapy treatment in osteosarcoma patients: a network meta-analysis of randomized controlled trials
Wang et al. Journal of Orthopaedic Surgery and Research (2017) 12:52 DOI 10.1186/s13018-017-0544-9 RESEARCH ARTICLE Open Access Effectiveness of multi-drug regimen chemotherapy treatment in osteosarcoma
More informationIntroduction. The HER2 Testing Expert Panel has identified five Clinical Questions that form the core of this Focused Update.
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/ College of American Pathologists Clinical Practice Guideline Focused Update Wolff, et al. Introduction
More informationThe Scandinavian Sarcoma Group annual report on extremity and trunk wall soft tissue and bone sarcomas
The Scandinavian Sarcoma Group annual report on extremity and trunk wall soft tissue and bone sarcomas 2012-2016 1 The SSG annual report on extremity and trunk wall soft tissue and bone sarcomas. The Scandinavian
More informationRoche presents updated results for investigational cancer immunotherapy atezolizumab in advanced bladder cancer
Media Release Basel, 8 January 2016 Roche presents updated results for investigational cancer immunotherapy atezolizumab in advanced bladder cancer Higher expression of PD-L1 (programmed death-ligand 1)
More informationSBRT in Pancreas Cancer Role of The Radiosurgery Society
SBRT in Pancreas Cancer Role of The Radiosurgery Society Anand Mahadevan MD FRCS FRCR Chairman Division of Radiation Oncology Geisinger Health System, Danville, PA, USA. Past President and Chairman: The
More informationAlicia K. Morgans, MD Assistant Professor of Medicine Division of Hematology/Oncology Vanderbilt University Medical Center January 24, 2015
Alicia K. Morgans, MD Assistant Professor of Medicine Division of Hematology/Oncology Vanderbilt University Medical Center January 24, 2015 Overview Background Perioperative chemotherapy in MIBC Neoadjuvant
More informationSafer Trials, Safer stenting Time to change your practice?
Safer Trials, Safer stenting Time to change your practice? Alison Halliday Professor of Vascular Surgery University of Oxford UK Stroke Forum Parallel Session 2B Carotid Stenosis Tuesday 29 th November
More information